

APPENDIX A: Coformulated and copackaged complete ARV regimens which should not be coadministered with other ARVs (DUR POS Edits)

Brand Names	Generic Drug Names
Biktarvy	Bictegravir/emtricitabine/tenofovir alafenamide
Cabenuva	Cabotegravir and rilpivirine
Complera	Rilpivirine/emtricitabine/tenofovir disoproxil fumarate
Delstrigo	Doravirine/lamivudine/tenofovir disoproxil fumarate
Dovato	Dolutegravir/lamivudine
Genvoya	Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Juluca	Dolutegravir/rilpivirine
Odefsey	Rilpivirine/emtricitabine/tenofovir alafenamide
Stribild	Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Symfi, Symfi Lo	Efavirenz/lamivudine/tenofovir disoproxil fumarate
Symtuza	Darunavir/cobicistat/emtricitabine/tenofovir alafenamide

ARV=antiretroviral; DUR=drug utilization review; POS=point of service

Notes on coformulated and copackaged ARVs:

FDA labeling for all products in Appendix A contains statements against use with other ARVs:

- Because BIKTARVY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended.¹
- Because CABENUVA is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended.²
- COMPLERA is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for treatment of HIV-1 infection is not recommended.³
- Because DELSTRIGO is a complete regimen, co-administration with other antiretroviral medications for treatment of HIV-1 infection is not recommended.⁴
- DOVATO is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral drugs for the treatment of HIV-1 infection is not recommended.⁵
- GENVOYA should not be administered with other antiretroviral medications for treatment of HIV-1 infection.⁶
- Because JULUCA is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended.⁷
- ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended.⁸
- STRIBILD is a complete regimen for the treatment of HIV-1 infection; therefore, STRIBILD should not be administered with other antiretroviral medications for treatment of HIV-1 infection.⁹



- SYMFI should not be administered with other antiretroviral medications for the treatment of HIV-1 infection.¹⁰
- SYMFI LO should not be administered with other antiretroviral medications for the treatment of HIV-1 infection.¹¹
- SYMTUZA is a complete regimen for HIV-1 infection and co-administration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended.¹²

Coformulated products which may be used with other ARVs:

- Atripla (efavirenz/tenofovir disoproxil fumarate/emtricitabine) label states that it is indicated as a complete regimen or in combination with other ARVs for treatment of HIV-1 infection.¹³
- Triumeq and Triumeq PD (dolutegravir/abacavir/lamivudine) label provides guidance for use with other ARVs.¹⁴

References:

1. Biktarvy. Prescribing information. Gilead Sciences, Inc.; October 2022. Accessed 9/13/2023.
2. Cabenuva. Prescribing information. ViiV Healthcare Company; February 2023. Accessed 9/13/2023.
3. Complera. Prescribing information. Gilead Sciences, Inc.; March 2021. Accessed 9/13/2023.
4. Delstrigo. Prescribing information. Merck Sharp & Dohme, LLC; November 2022. Accessed 9/13/2023.
5. Dovato. Prescribing information. ViiV Healthcare Company; January 2023. Accessed 9/13/2023.
6. Genvoya. Prescribing information. Gilead Sciences, Inc.; January 2022. Accessed 9/13/2023.
7. Juluca. Prescribing information. ViiV Healthcare Company; October 2022. Accessed 9/13/2023.
8. Odefsey. Prescribing information. Gilead Sciences, Inc.; February 2023. Accessed 9/13/2023.
9. Stribild. Prescribing information. Gilead Sciences, Inc.; March 2021. Accessed 9/13/2023.
10. Symfi. Prescribing information. Mylan Specialty LP; October 2019. Accessed 9/13/2023.
11. Symfi Lo. Prescribing information. Mylan Specialty LP; October 2019. Accessed 9/13/2023.
12. Symtuza. Prescribing information. Janssen Products LP; August 2023. Accessed 9/13/2023.
13. Atripla. Prescribing information. Gilead Sciences, LLC.; December 2021. Accessed 9/13/2023.
14. Triumeq and Triumeq PD. Prescribing information. ViiV Healthcare Company; June 2023. Accessed 9/13/2023.